Findimmune
Biotechnology spin-off from an academic cancer centre in France developing therapeutics that modulate innate immunity, with a focus on reprogramming tumor-associated macrophages. Research emphasis includes molecular radiotherapy, drug delivery and nanomedicine; development pipeline includes oncology and immune-inflammatory indications and a veterinary intratumoral study.
Industries
Nr. of Employees
small (1-50)
Products
F1901 (intratumoral innate immune enhancer)
Lead candidate developed for intratumoral administration to enhance innate immune responses in solid tumours; shown in murine models to induce immunogenic tumor cell death and enhance anti-PD-1 responses; being evaluated in a veterinary (canine) proof-of-concept clinical study.
F1902 (preactivated oxazaphosphorine derivative)
A preactivated oxazaphosphorine derivative engineered to release active species without generating harmful metabolites; designed for tumour-targeted delivery via self-nano-assembly to improve stability, biodistribution and therapeutic index; shows dose-dependent cytotoxic and immunomodulatory activity and synergy with anti-PD1 agents in preclinical models.
F2001 (macrophage-modulating agent for cytokine storm/ARDS)
Therapeutic candidate designed to modulate an innate immune checkpoint to reprogram pro-inflammatory alveolar macrophages toward an anti-inflammatory phenotype; intended to address cytokine storm in acute respiratory distress syndrome and other hyperinflammatory conditions.
F1902
A preactivated oxazaphosphorine derivative with immunomodulating properties designed to avoid toxic metabolic pathways and provide tumor cell specific targeting.
F1901
F1901 is an innate immune system enhancer indicated for canine oral solid tumors grade I to III such as melanoma and squamous cell carcinoma, and serves as a translational model for human cancer.
F2001
F2001 modulates an immune checkpoint to reprogram pro-inflammatory alveolar macrophages toward an anti-inflammatory phenotype in deep areas of the affected lung for treating ARDS.
F1901 (intratumoral innate immune enhancer)
Lead candidate developed for intratumoral administration to enhance innate immune responses in solid tumours; shown in murine models to induce immunogenic tumor cell death and enhance anti-PD-1 responses; being evaluated in a veterinary (canine) proof-of-concept clinical study.
F1902 (preactivated oxazaphosphorine derivative)
A preactivated oxazaphosphorine derivative engineered to release active species without generating harmful metabolites; designed for tumour-targeted delivery via self-nano-assembly to improve stability, biodistribution and therapeutic index; shows dose-dependent cytotoxic and immunomodulatory activity and synergy with anti-PD1 agents in preclinical models.
F2001 (macrophage-modulating agent for cytokine storm/ARDS)
Therapeutic candidate designed to modulate an innate immune checkpoint to reprogram pro-inflammatory alveolar macrophages toward an anti-inflammatory phenotype; intended to address cytokine storm in acute respiratory distress syndrome and other hyperinflammatory conditions.
F1902
A preactivated oxazaphosphorine derivative with immunomodulating properties designed to avoid toxic metabolic pathways and provide tumor cell specific targeting.
F1901
F1901 is an innate immune system enhancer indicated for canine oral solid tumors grade I to III such as melanoma and squamous cell carcinoma, and serves as a translational model for human cancer.
F2001
F2001 modulates an immune checkpoint to reprogram pro-inflammatory alveolar macrophages toward an anti-inflammatory phenotype in deep areas of the affected lung for treating ARDS.
Expertise Areas
- Immuno-oncology
- Macrophage reprogramming
- Molecular radiotherapy and radiobiology
- Drug delivery and nanomedicine
Key Technologies
- Macrophage phenotype programming
- Immune checkpoint modulation (innate immune checkpoints)
- Molecular radiotherapy approaches
- Self-assembling nanodrug formulations
News & Updates
A canine clinical trial testing intratumoral administration for safety and efficacy in oral melanoma and squamous cell carcinoma (20 dogs, dosing at D1, D30, D90; efficacy assessed by iRECIST). Principal Investigator: Dr Laura Barrett, VetAgro Sup.
A canine clinical trial testing intratumoral administration for safety and efficacy in oral melanoma and squamous cell carcinoma (20 dogs, dosing at D1, D30, D90; efficacy assessed by iRECIST). Principal Investigator: Dr Laura Barrett, VetAgro Sup.